CMS Francis Lefebvre, advisor to the co-founder and the management of Stingray Healthcare

Press release

CMS Francis Lefebvre advised the co-founder and the management of Stingray Healthcare in the context of the acquisition of the group by Fremman Capital.

Founded in 2017 in Switzerland by Jacobs Capital and Ralph Hefti, Stingray is an alliance of medical professionals, healthcare managers, and entrepreneurs dedicated to supporting the fight against cancer.

Stingray has built a strong presence in France and Germany, Europe’s two largest radiotherapy markets, operating 11 centres that deliver radiotherapy, radiosurgery and oncology treatments.

Following this acquisition, Fremman Capital will combine Stingray with Amethyst Radiotherapy, acquired in August 2025, to create the largest pan-European cancer care platform, with a presence across multiple European markets and a shared ambition to broaden access to high-quality cancer care. The new group will operate under the name Stingray Healthcare Group.

The CMS team was led by François Bossé-Cohic, Counsel with Louise Paysant, associate for the corporate aspects.

Pierre Dedieu, Partner and Inès Mzali, Counsel, advised on the French tax aspects and Valentina Santambrogio, Partner on the English aspects of the transaction.

The law firm Lenz & Staehelin also advised on the Swiss aspects of the transaction (Floran Ponce).

Jacobs Capital, seller, was advised by Linklaters and Fremman Capital, buyer, was advised par McDermott Will & Schulte.